¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"percent surface dose"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
high dose rate
°í¼±·®·ü
high dose rate intraluminal radiotherapy
°í¼±·®·ü°ü³»¹æ»ç¼±Ä¡·á
high dose tolerance
Ç׿ø°ú·®Çã¿ë
immunizing dose
¸é¿ª¿ë·®, ¸é¿ª·®
individual effective dose
°³ÀÎÀ¯È¿¿ë·®
infective dose
°¨¿°¿ë·®, °¨¿°·®
integral dose
ÀûºÐ¼±·®
lethal dose
1. Ä¡»ç¿ë·® 2. Ä¡»ç¼±·®
loading dose
ºÎÇϿ뷮, ºÎÇÏ·®
low dose rate
Àú¼±·®·ü
low dose rate irradiation
Àú¼±·®·üÁ¶»ç
low-dose tolerance
Ç׿ø¼Ò·®Çã¿ë
maintenance dose
À¯Áö¿ë·®
minimal effective dose
ÃÖ¼ÒÀ¯È¿·®
minimal erythema dose
ÃÖ¼ÒÈ«¹Ý¼±·®
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
dose-response curve
¿ë·®¹ÝÀÀ°î¼±
percentage depth dose curve
½ÉºÎ¼±·®¹éºÐÀ²°î¼±
sigmoid dose-response curve
±¸ºÒ¼±·®¹ÝÀÀ°î¼±
dose
¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
depth dose
½ÉºÎ¼±·®
dose distribution
¹æ»ç¼±·®ºÐÆ÷
dose profile
¹æ»ç¼±·®Ãø¸éµµ
dose rate
¼±·®·ü
dose rate effect
¼±·®À²È¿°ú
dose rate meter
¼±·®À²°è, ¼±·®·üÃøÁ¤±â
dose rate variation
¼±·®·üº¯ÀÌ
dose response relationship
¿ë·®¹ÝÀÀ°ü°è
doubling dose
¹è°¡¼±·®
effective dose
À¯È¿¿ë·®, À¯È¿¼±·®
erythema dose
È«¹Ý¼±·®
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
hepatitis B surface antigen (HBs Ag)
BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
hepatitis B surface antigen(HBs Ag)
BÇü °£¿°Ç¥¸éÇ׿ø
immunoglobulin, surface
¼¼Æ÷Ç¥¸é ¸é¿ª±Û·ÎºÒ¸°
impression of root surface
±Ù¸éÀλó(ÐÆØü ìÔßÚ).
incisal surface
Àý´Ü¸é(ôîÓ®Øü).
inferior articular surface
¾Æ·¡°üÀý¸é
inferior surface
¾Æ·¡¸é
inferior surface of petrous portion
¹ÙÀ§¾Æ·¡¸é
inferior surface of tongue
Çô¾Æ·¡¸é
plantar surface of toes
¹ß°¡¶ô¹Ù´Ú
popliteal surface
¿À±Ý¸é
posterior articular surface
µÚ°üÀý¸é
posterior articular surface for talus
µÚ¸ñ¸»°üÀý¸é
posterior calcaneal articular surface
µÚ¹ß±Á°üÀý¸é, ÈÄÁ¾°ñ°üÀý¸é(ýñ¢Íé Î¼ï½Øü).
posterior calcaneal articular surface
µÚ¹ß²ÞÄ¡°üÀý¸é
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
dose, median neutralization
50%ÁßÈ·®
dose, median tissue culture infective
50%Á¶Á÷¹è¾ç°¨¿°·®
dose, minimum hemagglutinating
ÀûÇ÷±¸ÀÀÁýÃÖ¼Ò·®
dose, minimum hemolytic
ÃÖ¼Ò¿ëÇ÷·®
dose-effect relationship
¼±·®¿µÇâ°ü°è
dose-equivalent commitment
¼±·®´ç·®¿¹Å¹
dose-equivalent limits
¼±·®´ç·®Çѵµ
dose-reduction factor
¼±·®°¨¼Ò°è¼ö
dose-response curve
¼±·®¹ÝÀÀ°î¼±
dose-response curve
¿ë·®¹ÝÀÀ°î¼±(éÄÕáÚãëëÍØàÊ)
dose-response relationship
¼±·®¹ÝÀÀ°ü°è
dose-volume histogram, DVH
¼±·®Ã¼ÀûÈ÷½ºÅä±×¶÷
dose-volume histograms
¼±·®Ã¼ÀûÇ¥
doubling dose
¹è°¡¼±·®(ÛÃÊ¥àÊåÖ).
effective dose
À¯È¿¼±·®
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½